Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical markers combined with HMGB1 polymorphisms to predict efficacy of conventional DMARDs in rheumatoid arthritis patients.

Clinical immunology (Orlando, Fla.) - 1 Dec 2020

Xu Ke, Ren Xiaoyu, Ju Bomiao, Aihaiti Yirixiati, Cai Yongsong, Zhang Yingang, He Lan, Wang Jing

Abstract excerpt

The efficacy of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) for rheumatoid arthritis (RA) patients was limited. However, there were no predictive markers for poor csDMARDs outcome. Clinical information of RA patients was collected and the high-mobility group box 1 (HMGB1) polymorphisms (rs4145277, rs2249825, rs1412125 and rs1045411) were examined. Among the 252 patients, 31.0% had no...

Read the complete abstract on PubMed

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antirheumatic Agents
Share to Arthritis, Rheumatoid
Share to Biomarkers
Share to Genotype
Share to HMGB1 Protein
Share to Polymorphism, Genetic
Share to Treatment Outcome

Source

Identifiers

PMID: 32920213
DOI: 10.1016/j.clim.2020.108592

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical markers combined with HMGB1 polymorphisms to predict efficacy of conventional DMARDs in rheumatoid arthritis patients.PMID 32920213Read ↗

Biomarkers to Personalize the Treatment of Rheumatoid Arthritis: Focus on Autoantibodies and PharmacogeneticsSemantic proximity Read ↗

Frontiers in Rheumatoid Arthritis: Emerging Research and Unmet Needs in Pharmacologic ManagementSemantic proximity Read ↗

Prognostic significance of high-mobility group box protein 1 genetic polymorphisms in rheumatoid arthritis disease outcome.Semantic proximity Read ↗

Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 TreatmentSemantic proximity Read ↗

Can rheumatoid arthritis responsiveness to methotrexate and biologics be predicted?Semantic proximity Read ↗

Genetic polymorphisms associated with therapeutic response and adverse effects to methotrexate in Taiwanese patients with rheumatoid arthritis: a real-world, hospital-based study.Semantic proximity Read ↗

DNA Methylation Signatures of Response to Conventional Synthetic and Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid ArthritisSemantic proximity Read ↗

Contribution of HLA-DRB1*04 alleles and anti-cyclic citrullinated antibodies to development of resistance to disease-modifying antirheumatic drugs in early rheumatoid arthritis.Semantic proximity Read ↗

Factors Predicting the Therapeutic Response to Methotrexate in Japanese Patients with Rheumatoid Arthritis: A Hospital-Based Cohort Study.Semantic proximity Read ↗

Are gene polymorphisms related to treatment outcomes of methotrexate in patients with rheumatoid arthritis? A systematic review and meta-analysis.Semantic proximity Read ↗

Circulating anti-citrullinated peptide antibodies, cytokines and genotype as biomarkers of response to disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.Semantic proximity Read ↗

Can we predict unresponsiveness to methotrexate in rheumatoid arthritis? A pharmacogenetic study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.